Investigation – Page 17

Supplier qualification gap during ISO 13485 audit: inspection-ready documentation

“`html Investigating Supplier Qualification Gaps During ISO 13485 Audits Supplier qualification is a critical process in ensuring that medical devices meet their regulatory requirements and perform consistently within the expected…

Labeling non-compliance during controlled drug manufacturing: inspection-ready documentation

Addressing Labeling Non-Compliance Issues During Controlled Drug Manufacturing Labeling non-compliance during controlled drug manufacturing presents significant risks to regulatory adherence and patient safety. When discrepancies arise—whether through wrong labels, incorrect…

Design control deficiency during FDA inspection: inspection-ready documentation

Addressing Design Control Deficiencies Uncovered During FDA Inspections In pharmaceutical manufacturing, design control deficiencies can lead to significant regulatory scrutiny, especially during FDA inspections. Learning to effectively identify, investigate, and…

Chain of custody breach during warehousing: regulatory enforcement risk mitigation

Mitigating Regulatory Risks from Chain of Custody Breaches in Pharmaceutical Warehousing In the pharmaceutical industry, maintaining a secure chain of custody is critical, particularly for controlled substances. A breach in…

Design control deficiency during ISO 13485 audit: regulatory remediation strategy

“`html Addressing Design Control Deficiencies in ISO 13485 Audits: A Comprehensive Investigation Strategy Design control deficiencies identified during ISO 13485 audits pose significant challenges to compliance and can jeopardize product…

Inventory reconciliation mismatch during distribution: CAPA and security controls

Addressing Inventory Reconciliation Discrepancies During Pharmaceutical Distribution In the highly regulated world of pharmaceutical manufacturing and distribution, maintaining accurate inventory records is critical. An inventory reconciliation mismatch during distribution can…

Design control deficiency during post-market surveillance: inspection-ready documentation

Addressing Design Control Deficiencies in Post-Market Surveillance: An Investigation Framework Post-market surveillance is critical for ensuring the ongoing safety and efficacy of medical devices. When design control deficiencies are identified,…

Labeling non-compliance during DEA/FDA inspection: CAPA and security controls

Addressing Non-Compliance in Labeling during DEA/FDA Inspections: Strategies for CAPA and Security Controls Labeling non-compliance during DEA/FDA inspections poses significant risks to pharmaceutical manufacturers, including regulatory penalties and potential product…

CAPA ineffectiveness during ISO 13485 audit: CAPA system strengthening

“`html Addressing CAPA System Weaknesses Identified During ISO 13485 Audits The pharmaceutical manufacturing landscape is continuously challenged by the need for regulatory compliance, particularly under ISO 13485 standards. A consistent…

Inventory reconciliation mismatch during distribution: inspection-ready documentation

Addressing Inventory Reconciliation Discrepancies During Distribution: An In-Depth Investigation Inventory reconciliation mismatches can create significant challenges in pharmaceutical distribution, raising concerns about adherence to Good Manufacturing Practices (GMP) and regulatory…

CAPA ineffectiveness in medical device manufacturing: regulatory remediation strategy

Addressing CAPA Ineffectiveness in Medical Device Manufacturing: A Strategic Approach In medical device manufacturing, ineffective Corrective and Preventive Actions (CAPA) can lead to regulatory non-compliance, delayed product releases, and significant…

Inventory reconciliation mismatch during controlled drug manufacturing: regulatory enforcement risk mitigation

Mitigating Regulatory Risks from Inventory Reconciliation Mismatches in Controlled Drug Manufacturing In the highly regulated landscape of pharmaceutical manufacturing, especially for controlled substances, inventory reconciliation mismatches can pose significant risks…